Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy

Haitao Pan,1,2 Jiayu Liu,1,2 Wentong Deng,1,2 Jieyu Xing,1,2 Qing Li,1,2 Zhong Wang1,2 1School of Pharmaceutical Sciences, 2Centre for Cellular & Structural Biology, Sun Yat-Sen University, Guangzhou, People’s Republic of China Introduction: Bispecific antibodies that engage immu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pan H, Liu J, Deng W, Xing J, Li Q, Wang Z
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
Fab
CEA
Acceso en línea:https://doaj.org/article/cb78cf8b29e247939918250ecc55b620
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!